Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide - Wikidata - wikimedia - TriplyDB

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

http://www.wikidata.org/entity/Q27701894

about

Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse.Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery.A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity.Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.An overview of new GLP-1 receptor agonists for type 2 diabetes.Controlled release of biologics for the treatment of type 2 diabetes.Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.Bioconjugation - using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers.Investigational glucagon-like peptide-1 agonists for the treatment of obesity.A Plethora of GLP-1 Agonists: Decisions About What to Use and When.Materials and methods for delivery of biological drugs.Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.Cardiovascular safety and benefits of GLP-1 receptor agonists.Lipopeptides as therapeutics: applications and in vivo quantitative analysis.GLP-1/glucagon receptor co-agonism for treatment of obesity.Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor.Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.Multifunctional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide Receptors.Semaglutide-the "new kid on the block" in the field of glucagon-like peptide-1 receptor agonists?Semaglutide seems to be more effective the other GLP-1Ras.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.Adapting the Glaser Reaction for Bioconjugation: Robust Access to Structurally Simple, Rigid Linkers.Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide.Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study.Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide.Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.Targeting GLP-1 receptor trafficking to improve agonist efficacy.SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide.Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Are peptide conjugates the golden therapy against obesity?

P2860

Q28067465-0D3BDCFF-ACC6-4E1C-9B6F-F3C24C744BB1 Q33825537-05B9F909-23A8-422B-A776-CE8201FBC9E2 Q36821353-D70E035C-C54D-4C75-A559-AD3FA073EE9A Q37116075-9E7B51A8-D490-498B-9FFA-F510C9AB4E72 Q37729181-DEBEEB72-C0DD-4083-A9AE-7BCB37051032 Q38639922-827D8EFD-4C02-4F4C-AA00-05339160E580 Q38665753-0C24D5C6-41F0-44D7-BA4E-DC016E59B51B Q38838461-9246A5F4-3CC0-4368-BCAC-52DAE0F4938D Q38866310-5BA27C08-8EA6-41F2-BDB9-F9CECB50EAD1 Q38909537-20F214FF-3807-42B3-A894-649FAEDC45C7 Q38937735-A5DB7662-787F-4993-BD6E-F7F620D97543 Q38987110-72E8CC41-34C5-4F76-B947-62B9AE572E60 Q38987392-FC8DE174-C668-437E-8B5C-690CFCB2B539 Q38989309-B6D1EA21-9D4A-4B2A-B152-89FD126ED04A Q39013056-A11062D5-1921-4A89-B24C-B07D638AF977 Q39037677-6598BEAC-E8DD-4B1D-A245-1B3E21635772 Q39451553-05E1FDC0-F72E-47C9-806E-AFA3216BE8C5 Q40998901-DCDCF26D-B8DD-4D01-80CC-DF5B977D0A46 Q41184651-052A4FB9-6094-4FC0-BD22-E55A956F3BC2 Q41539948-4A157885-5E2E-4E13-88F3-8B02DE94C4FF Q42266832-9F3392EE-80FC-4FC1-8150-213C3335FF82 Q43246916-B77CC318-6096-43B0-8FFF-6819509D93E9 Q46063056-427E0AD0-E5C5-4BF7-88D3-B7AA5E6DD086 Q47097015-4DCF3A70-EE4D-4207-84E7-6BDB570FE668 Q47114286-72C1F367-AEBD-499C-B90C-8A67A6DBCBE0 Q47590580-C80D2EFF-7B7A-4899-93EC-0477720BADA1 Q48161924-86C79746-C04D-468B-B128-74530A6A0312 Q48178209-6DA4FCB0-BD76-412A-8345-5E351D30E16E Q48219629-04C5E6C6-6468-47E4-A637-C7635544B1D1 Q48264116-12FA9DAB-FCDF-4F0A-B1AD-B6EA79C3F7B3 Q48300522-1B51D01C-1D65-4A72-96D5-D20A3B319467 Q50018586-55199908-B38A-4097-B537-3034E85A641F Q50134173-CA69F919-549D-46FC-82CA-28D3935B5BDD Q52580641-74B2B757-6DBB-4D74-9643-8B3132605EEA Q52656812-96E7E58E-6DC7-4BDC-AF39-13A1898B8ABC Q53281306-488332FD-D331-4829-8373-26D65446B401 Q55364507-9477E719-7D68-4DFB-8EE6-DFCE1DD6D941 Q55380047-F1B2F5BC-AECC-4B2D-B9EA-2D983A62F7D8 Q55401199-BB62772D-7C56-44AD-BE18-20CA153ACA00 Q55427238-212FA10B-82E7-4C39-A334-106676C83E19

P2860

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

http://www.wikidata.org/entity/Q27701894

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@ast

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@en

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@nl

type

label

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@ast

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@en

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@nl

prefLabel

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@ast

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@en

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@nl

P1433

Q27701894-B0EFA8CD-6732-45D7-BD01-E2F9E8C8645C

P1476

Q27701894-C8D0EFA5-199E-4175-B726-463414973D88

P2093

Q27701894-1071477F-01A2-432A-863D-4C96418F6BA5

Q27701894-14D26EEB-780A-4B2B-ABFF-E330B108C657

Q27701894-264AAD8D-BC0A-4679-88E2-ACC265C39C01

Q27701894-4B26728B-3F8D-4A9C-87FA-A55C15E0235B

Q27701894-513EDC14-9D9C-4D96-881C-BA8AE6B51C62

Q27701894-5B7231B8-34B0-473A-A11A-7F7A27F994A2

Q27701894-869C627C-9D10-4C52-9325-DB504096AAFE

Q27701894-89C20F2F-C528-4CB7-9404-F4D3151AEF94

Q27701894-89F25DB1-6F21-4C61-ABB2-BE27CDD42385

Q27701894-9AD04326-CBB2-4CAF-B9AF-4FD04D44020D

P304

Q27701894-AB736554-5F9E-438C-AC74-306547AA3B26

P31

Q27701894-0352FA23-D436-46B3-A819-359AF00AFA5F

P3181

Q27701894-48EE5605-2553-4FF8-9F24-11DC172522DF

P356

Q27701894-02487066-2E8F-422B-B710-3FB8E3CE24B2

P407

Q27701894-886F3A73-6A63-4908-A11C-C777078D9545

P433

Q27701894-4F6CB3CE-5618-4324-8F7D-6BEDF9F675C3

P478

Q27701894-EAC97522-227B-4A36-BF83-922931C4D328

P50

Q27701894-327F9802-2912-4E16-B23C-847A24DC64E6

P577

Q27701894-73212C5E-5B7F-4FE6-BC4B-D9C46B05E88A

P698

Q27701894-70881DC5-D3D5-41A4-8A84-C93A5D03BDB5

P3181

P356

ACS.JMEDCHEM.5B00726

P1433

Journal of Medicinal Chemistry

P1476

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

@en

P2093

Dorte X Gram

http://www.w3.org/2001/XMLSchema#string

Flemming Seier Nielsen

http://www.w3.org/2001/XMLSchema#string

Holger Martin Strauss

http://www.w3.org/2001/XMLSchema#string

Ingrid Pettersson

http://www.w3.org/2001/XMLSchema#string

Jacob Kofoed

http://www.w3.org/2001/XMLSchema#string

James McGuire

http://www.w3.org/2001/XMLSchema#string

Jane Spetzler

http://www.w3.org/2001/XMLSchema#string

Jesper Lau

http://www.w3.org/2001/XMLSchema#string

Kjeld Madsen

http://www.w3.org/2001/XMLSchema#string

Lauge Schäffer

http://www.w3.org/2001/XMLSchema#string

P304

7370-7380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1502119

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/ACS.JMEDCHEM.5B00726

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Dorte B Steensgaard

P577

2015-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26308095

http://www.w3.org/2001/XMLSchema#string